A combination chemoendocrine therapy of mitoxantrone, doxifluridine, and medroxyprogesterone acetate for anthracycline-resistant advanced breast cancer

• Published in: Cancer chemotherapy and pharmacology Vol. 41; no. 3; pp. 243 - 247
• Main Authors: IINO, Y, YOKOE, T, ISHIDA, T, YOKOMORI, T, FUJII, T, ENDO, K, SHIOZAKI, H, AIBA, S, TAKANO, A, KISHI, S, SUGAMATA, N, MAEMURA, M, TAKEI, H, HORIGUCHI, J, TAKEYOSHI, I, OHWADA, S, MORISHITA, Y, KUSABA, T
• Format: Journal Article
• Language: English
• Published: Berlin Springer 1998
• Subjects: Adult; Aged; Antibiotics, Antineoplastic - therapeutic use; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Breast Neoplasms - drug therapy; Chemotherapy; Drug Resistance, Neoplasm; Female; Floxuridine - administration & dosage; Humans; Medical sciences; Medroxyprogesterone - administration & dosage; Middle Aged; Mitoxantrone - administration & dosage; Pharmacology. Drug treatments; Antineoplastic agent; Human; Drug combination; Intravenous administration; Doxifluridine; Toxicity; Fluoropyrimidine derivatives; Malignant tumor; Progestagen; Resistance; Mammary gland diseases; Chemotherapy; Treatment; Antimetabolic; Medroxyprogesterone; Clinical trial; Female; Advanced stage; Anthracyclins; Mammary gland; Sex steroid hormone; Mitoxantrone
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/s002800050735

Between January 1993 and October 1995, 34 patients with anthracycline-resistant advanced breast cancer were treated with a combination chemoendocrine therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA). Of 34 patients, 28 were evaluable for efficacy of this combination therapy, and 30 including 2 for whom data were incomplete were assessed for adverse drug reactions. Adriamycin (ADM) was used for pretreatment in 12 patients, 4'-epi-ADM in 6, and THP-ADM in 12. In the eligible patients, 8.0 mg/m2 MIT was administered intravenously every 4 weeks, and 600 mg MPA and 600 mg 5'-DFUR were given orally every day. The median follow-up period was 25 weeks (range 2-90 weeks). The median cumulative dose of mitoxantrone was 66 mg (range 12-121 mg). Of the 28 patients, 11 (39.3%) responded to this combination therapy. As for response in relation to predominant site of lesion, 1 of 5 soft tissue lesions (20%) and 8 of 12 bone metastases (66.7%) showed a partial response, and one complete response and one partial response (25.0%) were seen in eight lung lesions. None of three pleural lesions responded to this therapy. The median duration of response was 31 +/- weeks (range 12-82 weeks). Adverse drug reactions were controllable or tolerable. Combined chemoendocrine therapy with a low dose of MIT is a well-tolerated and moderately effective regimen for the treatment of anthracycline-resistant advanced breast cancer.